Loading…

Click-to-Release: Cleavable Radioimmunoimaging with [ 89 Zr]Zr-DFO- Trans -Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio

One of the main challenges of PET imaging with Zr-labeled monoclonal antibodies (mAbs) remains the long blood circulation of the radiolabeled mAbs, leading to high background signals, decreasing image quality. To overcome this limitation, here we report the use of a bioorthogonal linker cleavage app...

Full description

Saved in:
Bibliographic Details
Published in:Theranostics 2023-01, Vol.13 (12), p.4004-4015
Main Authors: Vlastara, Maria, Rossin, Raffaella, Hoeben, Freek J M, de Roode, Kim E, Boswinkel, Milou, Kleijn, Laurens H J, Nagarajah, James, Rijpkema, Mark, Robillard, Marc S
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 4015
container_issue 12
container_start_page 4004
container_title Theranostics
container_volume 13
creator Vlastara, Maria
Rossin, Raffaella
Hoeben, Freek J M
de Roode, Kim E
Boswinkel, Milou
Kleijn, Laurens H J
Nagarajah, James
Rijpkema, Mark
Robillard, Marc S
description One of the main challenges of PET imaging with Zr-labeled monoclonal antibodies (mAbs) remains the long blood circulation of the radiolabeled mAbs, leading to high background signals, decreasing image quality. To overcome this limitation, here we report the use of a bioorthogonal linker cleavage approach (click-to-release chemistry) to selectively liberate [ Zr]Zr-DFO from -cyclooctene-functionalized trastuzumab (TCO-Tmab) in blood, following the administration of a tetrazine compound (trigger) in BT-474 tumor-bearing mice. We created a series of TCO-DFO constructs and evaluated their performance in [ Zr]Zr-DFO release from Tmab using different trigger compounds. The behavior of the best performing [ Zr]Zr-TCO-Tmab was studied in healthy mice first to determine the optimal dose of the trigger. To find the optimal time for the trigger administration, the rate of [ Zr]Zr-TCO-Tmab internalization was studied in BT-474 cancer cells. Finally, the trigger was administered 6 h or 24 h after [ Zr]Zr-TCO-Tmab- administration in tumor-bearing mice to liberate the [ Zr]Zr-DFO fragment. PET scans were obtained of tumor-bearing mice that received the trigger 6 h post-[ Zr]Zr-TCO-Tmab administration. The [ Zr]Zr-TCO-Tmab and trigger pair with the best properties exhibited 83% release in 50% mouse plasma. In tumor-bearing mice the tumor-blood ratios were markedly increased from 1.0 ± 0.4 to 2.3 ± 0.6 (p = 0.0057) and from 2.5 ± 0.7 to 6.6 ± 0.9 (p < 0.0001) when the trigger was administered at 6 h and 24 h post-mAb, respectively. Same day PET imaging clearly showed uptake in the tumor combined with a strongly reduced background due to the fast clearance of the released [ Zr]Zr-DFO-containing fragment from the circulation through the kidneys. This is the first demonstration of the use of -cyclooctene-tetrazine click-to-release chemistry to release a radioactive chelator from a mAb in mice to increase tumor-to-blood ratios. Our results suggest that click-cleavable radioimmunoimaging may allow for substantially shorter intervals in PET imaging with full mAbs, reducing radiation doses and potentially even enabling same day imaging.
doi_str_mv 10.7150/thno.84865
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10405837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2848228070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c338t-b7909c5123ca9aeea87dfa8af33e975990856be3a7c8eff48ad6b96e425774453</originalsourceid><addsrcrecordid>eNpVkcFuFSEUhonR2KZ24wMYlsaEygzDAG6MjlabNGnS3G5qDGGYM_eiM9ACU9Pu-uZybW1aFhwCX_4DfAi9ruiBqDh9nzc-HMhGtvwZ2q0kk0S0DX3-aL2D9lP6RctoaK0q9RLtMMF5U7diF912k7O_SQ7kFCYwCT7grtQr00-AT83ggpvnxZfZrJ1f4z8ub_APLBU-jz_PI_lyeELwKhqfMOmu7RSCzeCBlK2Ul5tlNj0-8jZuoxNeLXOI22afCziU_OzCK_RiNFOC_fu6h84Ov6667-T45NtR9-mYWMZkJr1QVFle1cwaZQCMFMNopBkZAyW4UlTytgdmhJUwjo00Q9urFpqaC9E0nO2hj3e5F0s_w2DB52gmfRHL0-K1DsbppyfebfQ6XOmq_BuXTJSEt_cJMVwukLKeXbIwTcZDWJKui4a6llTQgr67Q20MKUUYH_pUVG-96a03_c9bgd88vtkD-t8S-wvkmpWy</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2848228070</pqid></control><display><type>article</type><title>Click-to-Release: Cleavable Radioimmunoimaging with [ 89 Zr]Zr-DFO- Trans -Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central (PMC)</source><creator>Vlastara, Maria ; Rossin, Raffaella ; Hoeben, Freek J M ; de Roode, Kim E ; Boswinkel, Milou ; Kleijn, Laurens H J ; Nagarajah, James ; Rijpkema, Mark ; Robillard, Marc S</creator><creatorcontrib>Vlastara, Maria ; Rossin, Raffaella ; Hoeben, Freek J M ; de Roode, Kim E ; Boswinkel, Milou ; Kleijn, Laurens H J ; Nagarajah, James ; Rijpkema, Mark ; Robillard, Marc S</creatorcontrib><description>One of the main challenges of PET imaging with Zr-labeled monoclonal antibodies (mAbs) remains the long blood circulation of the radiolabeled mAbs, leading to high background signals, decreasing image quality. To overcome this limitation, here we report the use of a bioorthogonal linker cleavage approach (click-to-release chemistry) to selectively liberate [ Zr]Zr-DFO from -cyclooctene-functionalized trastuzumab (TCO-Tmab) in blood, following the administration of a tetrazine compound (trigger) in BT-474 tumor-bearing mice. We created a series of TCO-DFO constructs and evaluated their performance in [ Zr]Zr-DFO release from Tmab using different trigger compounds. The behavior of the best performing [ Zr]Zr-TCO-Tmab was studied in healthy mice first to determine the optimal dose of the trigger. To find the optimal time for the trigger administration, the rate of [ Zr]Zr-TCO-Tmab internalization was studied in BT-474 cancer cells. Finally, the trigger was administered 6 h or 24 h after [ Zr]Zr-TCO-Tmab- administration in tumor-bearing mice to liberate the [ Zr]Zr-DFO fragment. PET scans were obtained of tumor-bearing mice that received the trigger 6 h post-[ Zr]Zr-TCO-Tmab administration. The [ Zr]Zr-TCO-Tmab and trigger pair with the best properties exhibited 83% release in 50% mouse plasma. In tumor-bearing mice the tumor-blood ratios were markedly increased from 1.0 ± 0.4 to 2.3 ± 0.6 (p = 0.0057) and from 2.5 ± 0.7 to 6.6 ± 0.9 (p &lt; 0.0001) when the trigger was administered at 6 h and 24 h post-mAb, respectively. Same day PET imaging clearly showed uptake in the tumor combined with a strongly reduced background due to the fast clearance of the released [ Zr]Zr-DFO-containing fragment from the circulation through the kidneys. This is the first demonstration of the use of -cyclooctene-tetrazine click-to-release chemistry to release a radioactive chelator from a mAb in mice to increase tumor-to-blood ratios. Our results suggest that click-cleavable radioimmunoimaging may allow for substantially shorter intervals in PET imaging with full mAbs, reducing radiation doses and potentially even enabling same day imaging.</description><identifier>ISSN: 1838-7640</identifier><identifier>EISSN: 1838-7640</identifier><identifier>DOI: 10.7150/thno.84865</identifier><identifier>PMID: 37554267</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher</publisher><subject>Research Paper</subject><ispartof>Theranostics, 2023-01, Vol.13 (12), p.4004-4015</ispartof><rights>The author(s).</rights><rights>The author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405837/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405837/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,36990,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37554267$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vlastara, Maria</creatorcontrib><creatorcontrib>Rossin, Raffaella</creatorcontrib><creatorcontrib>Hoeben, Freek J M</creatorcontrib><creatorcontrib>de Roode, Kim E</creatorcontrib><creatorcontrib>Boswinkel, Milou</creatorcontrib><creatorcontrib>Kleijn, Laurens H J</creatorcontrib><creatorcontrib>Nagarajah, James</creatorcontrib><creatorcontrib>Rijpkema, Mark</creatorcontrib><creatorcontrib>Robillard, Marc S</creatorcontrib><title>Click-to-Release: Cleavable Radioimmunoimaging with [ 89 Zr]Zr-DFO- Trans -Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio</title><title>Theranostics</title><addtitle>Theranostics</addtitle><description>One of the main challenges of PET imaging with Zr-labeled monoclonal antibodies (mAbs) remains the long blood circulation of the radiolabeled mAbs, leading to high background signals, decreasing image quality. To overcome this limitation, here we report the use of a bioorthogonal linker cleavage approach (click-to-release chemistry) to selectively liberate [ Zr]Zr-DFO from -cyclooctene-functionalized trastuzumab (TCO-Tmab) in blood, following the administration of a tetrazine compound (trigger) in BT-474 tumor-bearing mice. We created a series of TCO-DFO constructs and evaluated their performance in [ Zr]Zr-DFO release from Tmab using different trigger compounds. The behavior of the best performing [ Zr]Zr-TCO-Tmab was studied in healthy mice first to determine the optimal dose of the trigger. To find the optimal time for the trigger administration, the rate of [ Zr]Zr-TCO-Tmab internalization was studied in BT-474 cancer cells. Finally, the trigger was administered 6 h or 24 h after [ Zr]Zr-TCO-Tmab- administration in tumor-bearing mice to liberate the [ Zr]Zr-DFO fragment. PET scans were obtained of tumor-bearing mice that received the trigger 6 h post-[ Zr]Zr-TCO-Tmab administration. The [ Zr]Zr-TCO-Tmab and trigger pair with the best properties exhibited 83% release in 50% mouse plasma. In tumor-bearing mice the tumor-blood ratios were markedly increased from 1.0 ± 0.4 to 2.3 ± 0.6 (p = 0.0057) and from 2.5 ± 0.7 to 6.6 ± 0.9 (p &lt; 0.0001) when the trigger was administered at 6 h and 24 h post-mAb, respectively. Same day PET imaging clearly showed uptake in the tumor combined with a strongly reduced background due to the fast clearance of the released [ Zr]Zr-DFO-containing fragment from the circulation through the kidneys. This is the first demonstration of the use of -cyclooctene-tetrazine click-to-release chemistry to release a radioactive chelator from a mAb in mice to increase tumor-to-blood ratios. Our results suggest that click-cleavable radioimmunoimaging may allow for substantially shorter intervals in PET imaging with full mAbs, reducing radiation doses and potentially even enabling same day imaging.</description><subject>Research Paper</subject><issn>1838-7640</issn><issn>1838-7640</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVkcFuFSEUhonR2KZ24wMYlsaEygzDAG6MjlabNGnS3G5qDGGYM_eiM9ACU9Pu-uZybW1aFhwCX_4DfAi9ruiBqDh9nzc-HMhGtvwZ2q0kk0S0DX3-aL2D9lP6RctoaK0q9RLtMMF5U7diF912k7O_SQ7kFCYwCT7grtQr00-AT83ggpvnxZfZrJ1f4z8ub_APLBU-jz_PI_lyeELwKhqfMOmu7RSCzeCBlK2Ul5tlNj0-8jZuoxNeLXOI22afCziU_OzCK_RiNFOC_fu6h84Ov6667-T45NtR9-mYWMZkJr1QVFle1cwaZQCMFMNopBkZAyW4UlTytgdmhJUwjo00Q9urFpqaC9E0nO2hj3e5F0s_w2DB52gmfRHL0-K1DsbppyfebfQ6XOmq_BuXTJSEt_cJMVwukLKeXbIwTcZDWJKui4a6llTQgr67Q20MKUUYH_pUVG-96a03_c9bgd88vtkD-t8S-wvkmpWy</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Vlastara, Maria</creator><creator>Rossin, Raffaella</creator><creator>Hoeben, Freek J M</creator><creator>de Roode, Kim E</creator><creator>Boswinkel, Milou</creator><creator>Kleijn, Laurens H J</creator><creator>Nagarajah, James</creator><creator>Rijpkema, Mark</creator><creator>Robillard, Marc S</creator><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230101</creationdate><title>Click-to-Release: Cleavable Radioimmunoimaging with [ 89 Zr]Zr-DFO- Trans -Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio</title><author>Vlastara, Maria ; Rossin, Raffaella ; Hoeben, Freek J M ; de Roode, Kim E ; Boswinkel, Milou ; Kleijn, Laurens H J ; Nagarajah, James ; Rijpkema, Mark ; Robillard, Marc S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c338t-b7909c5123ca9aeea87dfa8af33e975990856be3a7c8eff48ad6b96e425774453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Research Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vlastara, Maria</creatorcontrib><creatorcontrib>Rossin, Raffaella</creatorcontrib><creatorcontrib>Hoeben, Freek J M</creatorcontrib><creatorcontrib>de Roode, Kim E</creatorcontrib><creatorcontrib>Boswinkel, Milou</creatorcontrib><creatorcontrib>Kleijn, Laurens H J</creatorcontrib><creatorcontrib>Nagarajah, James</creatorcontrib><creatorcontrib>Rijpkema, Mark</creatorcontrib><creatorcontrib>Robillard, Marc S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Theranostics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vlastara, Maria</au><au>Rossin, Raffaella</au><au>Hoeben, Freek J M</au><au>de Roode, Kim E</au><au>Boswinkel, Milou</au><au>Kleijn, Laurens H J</au><au>Nagarajah, James</au><au>Rijpkema, Mark</au><au>Robillard, Marc S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Click-to-Release: Cleavable Radioimmunoimaging with [ 89 Zr]Zr-DFO- Trans -Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio</atitle><jtitle>Theranostics</jtitle><addtitle>Theranostics</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>13</volume><issue>12</issue><spage>4004</spage><epage>4015</epage><pages>4004-4015</pages><issn>1838-7640</issn><eissn>1838-7640</eissn><abstract>One of the main challenges of PET imaging with Zr-labeled monoclonal antibodies (mAbs) remains the long blood circulation of the radiolabeled mAbs, leading to high background signals, decreasing image quality. To overcome this limitation, here we report the use of a bioorthogonal linker cleavage approach (click-to-release chemistry) to selectively liberate [ Zr]Zr-DFO from -cyclooctene-functionalized trastuzumab (TCO-Tmab) in blood, following the administration of a tetrazine compound (trigger) in BT-474 tumor-bearing mice. We created a series of TCO-DFO constructs and evaluated their performance in [ Zr]Zr-DFO release from Tmab using different trigger compounds. The behavior of the best performing [ Zr]Zr-TCO-Tmab was studied in healthy mice first to determine the optimal dose of the trigger. To find the optimal time for the trigger administration, the rate of [ Zr]Zr-TCO-Tmab internalization was studied in BT-474 cancer cells. Finally, the trigger was administered 6 h or 24 h after [ Zr]Zr-TCO-Tmab- administration in tumor-bearing mice to liberate the [ Zr]Zr-DFO fragment. PET scans were obtained of tumor-bearing mice that received the trigger 6 h post-[ Zr]Zr-TCO-Tmab administration. The [ Zr]Zr-TCO-Tmab and trigger pair with the best properties exhibited 83% release in 50% mouse plasma. In tumor-bearing mice the tumor-blood ratios were markedly increased from 1.0 ± 0.4 to 2.3 ± 0.6 (p = 0.0057) and from 2.5 ± 0.7 to 6.6 ± 0.9 (p &lt; 0.0001) when the trigger was administered at 6 h and 24 h post-mAb, respectively. Same day PET imaging clearly showed uptake in the tumor combined with a strongly reduced background due to the fast clearance of the released [ Zr]Zr-DFO-containing fragment from the circulation through the kidneys. This is the first demonstration of the use of -cyclooctene-tetrazine click-to-release chemistry to release a radioactive chelator from a mAb in mice to increase tumor-to-blood ratios. Our results suggest that click-cleavable radioimmunoimaging may allow for substantially shorter intervals in PET imaging with full mAbs, reducing radiation doses and potentially even enabling same day imaging.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher</pub><pmid>37554267</pmid><doi>10.7150/thno.84865</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1838-7640
ispartof Theranostics, 2023-01, Vol.13 (12), p.4004-4015
issn 1838-7640
1838-7640
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10405837
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central (PMC)
subjects Research Paper
title Click-to-Release: Cleavable Radioimmunoimaging with [ 89 Zr]Zr-DFO- Trans -Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T13%3A19%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Click-to-Release:%20Cleavable%20Radioimmunoimaging%20with%20%5B%2089%20Zr%5DZr-DFO-%20Trans%20-Cyclooctene-Trastuzumab%20Increases%20Tumor-to-Blood%20Ratio&rft.jtitle=Theranostics&rft.au=Vlastara,%20Maria&rft.date=2023-01-01&rft.volume=13&rft.issue=12&rft.spage=4004&rft.epage=4015&rft.pages=4004-4015&rft.issn=1838-7640&rft.eissn=1838-7640&rft_id=info:doi/10.7150/thno.84865&rft_dat=%3Cproquest_pubme%3E2848228070%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c338t-b7909c5123ca9aeea87dfa8af33e975990856be3a7c8eff48ad6b96e425774453%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2848228070&rft_id=info:pmid/37554267&rfr_iscdi=true